Extracellular vesicles, particularly exosomes and microvesicles, carry an array of bioactive molecules, including proteins, lipids, and RNA, making them essential in intercellular communication. The significance of EVs in tumorigenesis has garnered attention for their involvement in various cancer types. They not only modulate the tumor microenvironment but also facilitate the acquisition of traits that promote cancer cell survival, proliferation, and metastasis. The mechanisms through which EVs operate present a fertile ground for research, particularly within the context of endometrial cancer, a malignancy that often proves resistant to conventional therapies.

Endometrial cancer cells can significantly alter the phenotype and function of TAMs through EVs. The relationship between these two cell types is crucial in shaping the tumor microenvironment. Through the transfer of specific RNA molecules and proteins within these vesicles, cancer cells can effectively ‘reprogram’ the macrophages, promoting a more supportive environment for tumor progression. This transformation is instrumental, as TAMs can be polarized into pro-tumorigenic or anti-tumorigenic phenotypes, ultimately influencing disease outcomes.

Research into the cargo of EVs derived from endometrial cancer cells reveals that they carry signaling molecules which may stimulate TAMs, leading to enhanced tumor growth. For instance, the presence of certain cytokines and growth factors within these EVs can push macrophages towards a phenotype that supports tumorigenesis, facilitating angiogenesis and immune evasion. Such findings underscore the importance of understanding the molecular signatures of EVs as potential biomarkers for cancer progression and prognosis.

Moreover, the therapeutic implications of targeting EVs in endometrial cancer are profound. By disrupting the communication pathways mediated by these vesicles, it may be possible to hinder the supportive role of TAMs, thereby enhancing the efficacy of existing therapies. As resistance to chemotherapy and targeted therapies remains a significant hurdle in the management of endometrial cancer, strategies that disrupt the EV-TAM communication axis could provide a novel approach to overcome this challenge.

The role of EVs in fostering a tumor-promoting environment is underscored by their involvement in the epithelial-mesenchymal transition (EMT), a process critical for cancer metastasis. EVs can facilitate the transfer of molecules that induce EMT in adjacent normal cells, converting them into cells that exhibit cancer stem cell-like properties. This cross-talk not only aids in the cancer cell’s mobility and invasiveness but also contributes to the makeup of the tumor microenvironment, further entrenching the tumor’s malignant behavior.

Additionally, the potential for using EVs as therapeutic vehicles is an exciting area of research. Due to their natural role in intercellular communication, EVs can be engineered to deliver therapeutic agents specifically to tumor-associated macrophages, providing a targeted approach to therapy. This novel method could enhance treatment outcomes while minimizing off-target effects, aligning with the growing trend toward personalized medicine in oncology.

In the context of immunotherapy, understanding the interplay between endometrial cancer cells, EVs, and TAMs could unveil new strategies for enhancing immune responses. EVs have been shown to carry immunosuppressive factors, which can dampen anti-tumor immunity. By deciphering the complex dynamics of EVs and their immune modulation, researchers hope to develop strategies that counteract these effects, reinvigorating the body’s immune system to combat cancer more effectively.

Moreover, expanding our knowledge of the molecular content of EVs can lead to the identification of novel biomarkers for early diagnosis and treatment monitoring in endometrial cancer. The presence of specific nucleic acids or proteins in the circulation has the potential to serve as non-invasive indicators of disease state, guiding treatment decision-making and improving patient prognostication.

While the promise of EV research is remarkable, several challenges remain. The complexity of EV biology requires advanced characterization techniques to elucidate their precise roles and mechanisms in cancer biology. Furthermore, ethical considerations and regulatory frameworks surrounding the use of biological materials must also be addressed as research advances towards clinical applications.

Endometrial cancer, largely affecting postmenopausal women, represents a significant health concern with rising incidence rates. The exploration of EVs in this context not only enhances our understanding of tumor biology but also paves the way for innovative therapeutic strategies. The dialogue between cancer cells and the immune system, as mediated by EVs, is a promising frontier that calls for further investigation to unlock the full potential of this unique mode of communication in cancer therapy.

As scientific inquiry advances, the potential of extracellular vesicles continues to unfold. From their role as messengers in cancer communication to their utility as vehicles for targeted therapy, EVs are at the forefront of cancer research, promising to bridge gaps in our understanding and treatment of endometrial cancer and beyond.

With ongoing studies and a deeper understanding of these cellular entities, the future of cancer treatment may well hinge on the successful manipulation of extracellular vesicle pathways. Shaping the conversation between tumor cells and the immune system is integral to formulating biologically-informed therapies that could revolutionize the landscape of cancer management.

The journey towards harnessing the power of extracellular vesicles is just beginning, but the insights gained thus far indicate a transformative potential in the fight against cancer, particularly in cases such as endometrial cancer where traditional therapies have fallen short of efficacy.

Subject of Research: The role of extracellular vesicles in the communication between endometrial cancer cells and tumor-associated macrophages.

Article Title: The role of extracellular vesicles in the communication between endometrial cancer cells and tumour-associated macrophages: a review.

Article References:

Li, F., Shi, W. The role of extracellular vesicles in the communication between endometrial cancer cells and tumour-associated macrophages: a review.
J Cancer Res Clin Oncol 151, 286 (2025). https://doi.org/10.1007/s00432-025-06318-3

Image Credits: AI Generated

DOI:

Keywords: Endometrial cancer, extracellular vesicles, tumor-associated macrophages, cancer communication, therapy resistance.

Endometrial cancer typically responds well to surgical intervention in its initial stages, primarily through hysterectomy, which offers a high chance of remission. However, disseminated or recurrent forms pose a daunting clinical challenge due to the lack of effective molecularly tailored therapies. Conventional chemotherapies and radiation therapies tend to fall short either by limited efficacy or significant toxicity. Hence, the integration of molecular imaging with targeted agents—theranostics—stands as a beacon of hope for improving patient stratification, enabling personalized treatment regimens, and ultimately enhancing survival outcomes.

In pursuit of this goal, the investigative team embarked on an in-depth evaluation of three candidate biomarkers: HER2, mucin-16 (MUC16), and CD24. These antigens were selected based on their reported expression patterns in various cancers and their suitability as targets for molecular imaging and targeted radionuclide therapies. Employing immunohistochemistry and cell-based assays, the researchers assessed their expression in both healthy uterine/endometrial tissues and endometrial cancer-derived cell lines and patient tissues, providing a comprehensive comparative framework to identify differential overexpression amenable to nuclear medicine applications.

Central to this exploration was the generation of specialized immunoPET probes conjugated with Zirconium-89 (^89Zr), a positron-emitting radioisotope favored for its optimal half-life suited to antibody-based imaging. Specifically, ^89Zr-DFO-trastuzumab targeted HER2, ^89Zr-DFO-AR9.6 was directed against MUC16, and ^89Zr-DFO-ATG-031 targeted CD24. The design hinged on the principle that radiolabeled monoclonal antibodies selectively bind to their cognate antigens on tumor cells, enabling precise in vivo visualization and quantification through PET imaging.

Subsequent in vivo investigations utilized mouse models harboring subcutaneous xenografts developed from endometrial cancer cell lines as well as patient-derived xenografts (PDX). These murine models served as robust platforms to evaluate the biodistribution, tumor targeting efficiency, and imaging contrast of the radiotracers. Intriguingly, the CD24-targeted probe ^89Zr-DFO-ATG-031 consistently demonstrated the highest tumor uptake coupled with superior tumor-to-background ratios, highlighting its potential as a front-runner for radiotheranostic applications. Conversely, ^89Zr-DFO-trastuzumab exhibited moderate but nonetheless promising tumor localization, while the MUC16-targeting agent provided suboptimal imaging results, underscoring the heterogeneity of antigen accessibility and probe performance.

Mechanistically, CD24 is a glycosylphosphatidylinositol-anchored cell surface protein implicated in tumor progression and metastasis through modulation of cell adhesion and immune evasion pathways. Its overexpression in aggressive endometrial tumors may render it a valuable biomarker for both imaging and therapeutic intervention. HER2, a well-established oncogenic receptor tyrosine kinase, holds a legacy of clinical relevance in breast and gastric cancers; its emerging role in endometrial cancer introduces possibilities for repurposing trastuzumab-based therapeutic strategies augmented by diagnostic imaging.

The dual capability of these radiolabeled antibodies to identify tumor antigen expression non-invasively while simultaneously serving as vehicles for radionuclide therapy embodies the essence of theranostics—melding diagnostic precision with personalized treatment. PET imaging facilitates the selection of patients who express the target antigen at sufficient levels, thereby optimizing dosing and minimizing off-target effects. Therapeutically, these agents can be modified to deliver cytotoxic radioisotopes, such as alpha or beta emitters, directly to malignant cells, enabling targeted cellular destruction with limited systemic exposure.

Beyond the laboratory, the clinical translation of HER2 and CD24-targeted radiotheranostics bears significant implications. For patients with recurrent or metastatic endometrial cancer who currently face limited options, these strategies may offer new hope in terms of improved detection, therapy guidance, and real-time monitoring of treatment response. Moreover, the utilization of immunoPET probes can streamline drug development pipelines by providing robust biomarkers for therapeutic efficacy, expediting regulatory approvals.

The researchers emphasize that while MUC16 did not demonstrate encouraging imaging properties in this context, the comprehensive evaluation approach establishes a valuable template for future biomarker validation efforts. By integrating molecular biology, radiochemistry, and preclinical imaging, this study charts a course for systematic identification of viable radiotheranostic targets in understudied malignancies beyond the traditional scope.

Dr. Brian M. Zeglis, senior author and noted expert in nuclear chemistry, highlights the novelty and necessity of this approach in endometrial cancer. He stresses that advancing these radiotheranostic probes into clinical trials will require collaborative efforts spanning academia, industry, and regulatory bodies. Nevertheless, the promising preclinical data underscore the transformative potential of molecularly guided nuclear medicine techniques in addressing pressing unmet needs in oncology.

Such investigations align with the broader trend towards precision oncology, where therapeutics are tailored based on individual tumor biology rather than conventional histopathological classification. Leveraging PET imaging with radiolabeled antibodies not only refines diagnosis but also furthers understanding of tumor heterogeneity, receptor dynamics, and resistance mechanisms at a molecular level. This integrative paradigm could pave the way for iterative improvements in patient outcomes through adaptive treatment strategies.

In conclusion, the identification of HER2 and CD24 as robust radiotheranostic targets offers a new frontier in the molecular imaging and treatment of endometrial cancer. The study’s rigorous experimental design, coupled with insightful interpretation of imaging and biodistribution data, positions these molecular targets at the forefront of forthcoming clinical applications. As the quest for effective management of advanced endometrial cancer intensifies, such innovations herald a paradigm shift toward more precise, effective, and personalized nuclear medicine interventions.

Subject of Research: Animals

Article Title: Evaluating Radiotheranostic Targets for Endometrial Cancer

News Publication Date: September 4, 2025

Web References:
https://doi.org/10.2967/jnumed.125.270318

References:
Sebastiano et al., J Nucl Med 2025; jnumed.125.270318

Image Credits:
Sebastiano et al., J Nucl Med 2025; jnumed.125.270318

Keywords:
Cancer treatments, Biomarkers, Cancer

Central to this investigation is the mutation of the gene encoding Exportin-1 (XPO1), a crucial cellular regulator responsible for the nucleocytoplasmic transport of proteins and RNA. The specific mutation under scrutiny, XPO1^R749Q, has been identified as a rare but significant factor in colorectal as well as endometrial cancers. While the mutation itself does not accelerate tumor proliferation, it plays a key role in enabling tumor cells to resist chemotherapeutic agents, particularly irinotecan, a DNA replication inhibitor commonly used in colorectal cancer treatment protocols.

Dr. Taylor’s team utilized CRISPR-Cas9 genome editing to introduce the XPO1^R749Q mutation into human colorectal tumor cell lines to precisely interrogate its functional consequences. Their experiments elucidated that this mutation confers resistance to irinotecan by enhancing cellular DNA repair mechanisms. Specifically, the mutation appears to augment the activity of Replication Protein A (RPA), a pivotal protein involved in the DNA damage response, thereby enabling tumor cells to survive despite the genotoxic stress induced by chemotherapy.

Further compounding the complexity of these tumors, XPO1^R749Q mutations were found to often co-occur with mutations in the POLE gene—another mutation associated with a hypermutated state and extensive DNA damage. This co-mutation pattern underscores a sophisticated balance within tumor cells, wherein the DNA damage inflicted by POLE mutations is counteracted by the heightened repair capability driven by XPO1^R749Q, facilitating chemoresistance.

Encouragingly, the study revealed that targeting XPO1 with the selective inhibitor selinexor can effectively kill tumor cells harboring the R749Q mutation. Selinexor is already clinically approved for certain hematologic malignancies and is showing potential in endometrial cancer maintenance therapy. When combined with irinotecan, selinexor produced significantly reduced tumor volumes in preclinical colorectal cancer models, suggesting a synergistic therapeutic effect capable of overcoming existing drug resistance.

One of the most compelling findings is that the combination of selinexor and irinotecan may prove effective even in colorectal tumors without the XPO1 mutation. This is due to the fact that elevated levels of wild-type XPO1 are frequently observed across various solid tumors, which may render them susceptible to XPO1 inhibition. Hence, Dr. Taylor posits that this dual-drug regimen could have far-reaching applications beyond mutation-specific contexts.

Dr. Jaime Merchán, co-leader of the Translational and Clinical Oncology Research Program at Sylvester, emphasizes the clinical viability of these findings. He points out that this work not only provides a scientific rationale for new treatment protocols but also creates a viable path for transitioning from bench research to bedside application, potentially reshaping standard care for patients afflicted with advanced colorectal cancer.

The research owes much to extensive data analysis encompassing genomic profiles from over 217,000 cancer patients, enabling the identification of XPO1^R749Q mutation prevalence across solid tumors. This massive dataset highlights the mutation’s rarity but also its critical importance in the broader context of chemoresistance. These insights are the product of collaborative efforts between Sylvester and the Masonic Cancer Center at the University of Minnesota, where molecular oncologist Hai Dang Nguyen provided key contributions to unraveling the mutation’s mechanistic effects.

Future research spearheaded by Dr. Taylor and his postdoctoral associate Tulasigeri M. Totiger is set to explore whether the mechanistic pathways influenced by XPO1^R749Q operate similarly in endometrial cancer models. In addition, there is a strategic plan to assay the efficacy of combining selinexor with immunotherapy agents to amplify anti-tumor immune responses, thus expanding the therapeutic repertoire against resistant solid tumors.

This innovative study is supported by funding from the U.S. National Institutes of Health and institutional resources from Sylvester Comprehensive Cancer Center. Dr. Taylor underscores the importance of translational science in his approach, aiming to rapidly deliver tangible benefits for patients by leveraging molecular insights garnered from leukemia research and applying them to distinctly different solid tumor types.

As the research community grapples with the challenge of overcoming chemotherapy resistance—a major barrier to effective cancer treatment—this study shines a beacon of hope. It pioneers a new conceptual framework by integrating molecular genetics, DNA repair biology, and pharmacology to surmount obstacles that have long plagued colorectal cancer therapy. The implications of these findings could revolutionize clinical workflows and improve survival outcomes for countless patients.

By illuminating the interplay between nuclear export mechanisms and DNA damage repair pathways, Dr. Taylor’s work not only deepens our understanding of tumor cell biology but also paves the way for the development of next-generation therapeutics that exploit vulnerabilities in the cancer cell’s defense systems. If successfully translated into the clinic, this could mark a paradigm shift in how clinicians approach treatment-resistant colorectal and endometrial cancers.

The Stanley J. Glaser Foundation Research Award that enabled this research serves to recognize and propel outstanding faculty scientists by providing critical financial support for high-impact projects. With this backing, Dr. Taylor’s groundbreaking investigation is poised to move beyond preclinical stages toward clinical trials, with the ultimate goal of delivering more effective, personalized cancer therapies.

As cancer remains among the leading causes of morbidity and mortality worldwide, discoveries such as these underscore the indispensable role of genetic and translational research in combating this complex disease. Through strategic targeting of molecular pathways like those involving XPO1 mutations, the future of oncology promises more tailored, efficacious treatments that can better overcome drug resistance and improve long-term patient prognosis.

Subject of Research: Targeting XPO1 R749Q Mutations to Overcome Chemoresistance in Colorectal and Endometrial Cancers

Article Title: XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance

News Publication Date: June 18, 2025

Web References:

• University of Miami/Taylor Lab
• Sylvester Comprehensive Cancer Center
• Cancer Research Journal – Article DOI

References:

• Taylor J, Nguyen HD, et al. XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can be Targeted to Overcome Chemoresistance. Cancer Research. 2025.

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Colorectal cancer, colon cancer, molecular genetics, mutation, cancer, chemoresistance, XPO1, selinexor, irinotecan, DNA repair, CRISPR-Cas9, translational oncology

Endometrial cancer, one of the most common gynecological malignancies, poses a significant health burden worldwide. Its association with obesity has been well-documented, yet until now, the precise role that distinct abdominal fat compartments play in the disease’s progression and clinical outcomes has remained elusive. This study pioneers the quantitative exploration of total abdominal fat volume (TAV), subcutaneous abdominal fat volume (SAV), visceral abdominal fat volume (VAV), and the critical ratio of visceral to total fat percentage (VAV%), offering an unprecedented opportunity to understand fat’s nuanced influence on tumor biology.

At the forefront of this research is the use of CT scans acquired at the time of initial diagnosis in a substantial cohort of 293 endometrial cancer patients. This imaging modality allowed for the precise measurement of fat volumes within the abdomen, classifying fat into its two key compartments: subcutaneous, which lies beneath the skin, and visceral, which is found deeper, surrounding internal organs. This distinction is vital, as visceral fat is known to be metabolically active and implicated in chronic inflammation, insulin resistance, and other mechanisms that may promote cancer progression.

One of the pivotal findings revealed that VAV% — the proportion of visceral fat relative to total abdominal fat — significantly correlates with high-risk histologic subtypes of endometrial cancer. Patients exhibiting higher VAV% values were more likely to have aggressive tumor features, including high-grade endometrioid carcinoma and non-endometrioid histologies, which are historically linked to poorer clinical outcomes. This relationship underscores the potential of visceral fat measurement as a biomarker for tumor aggressiveness, assisting clinicians in risk stratification from the outset.

Further analysis unravelled a significant association between elevated VAV% and myometrial invasion, a key factor that describes the extent to which cancer penetrates the muscular layer of the uterus. This invasion depth is critical for staging and prognostication. Additionally, patients with lymphovascular space invasion (LVSI), which reflects the cancer’s ability to disseminate via lymphatic and blood vessels, also demonstrated higher visceral fat percentages. These findings collectively suggest that visceral adiposity might foster a tumor microenvironment conducive to invasive behavior and metastasis.

Beyond diagnostic implications, the study’s longitudinal design offered unique insight into fat dynamics by following 152 patients through serial CT scans a median of 13 months post-diagnosis. Intriguingly, the researchers documented a marked decrease in total, visceral, and subcutaneous fat compartments over this follow-up period. Such changes occurred during or after therapeutic interventions, which often include surgery, chemotherapy, or radiotherapy, known to exert systemic metabolic effects including weight loss.

Crucially, those patients who experienced disease progression during follow-up exhibited a more pronounced reduction in visceral fat compared to their progression-free counterparts. This suggests a complex interaction where not only the quantity of visceral fat but also its temporal loss may serve as an indicator of disease trajectory. The mechanisms could involve cancer cachexia, treatment-related metabolic alterations, or inflammatory responses associated with tumor advancement.

The implications of this visceral fat loss are profound. While obesity is a recognized risk factor for endometrial cancer development, the rapid depletion of visceral fat during ongoing disease may paradoxically herald a worsening clinical course. This dichotomy emphasizes the importance of nuanced fat monitoring, moving beyond simple measurements of body mass index (BMI) to focus on fat distribution and changes therein.

From a clinical perspective, integration of CT-derived fat assessments into routine evaluation presents an opportunity to enhance personalized treatment frameworks. Patients with high visceral fat percentages at diagnosis might benefit from tailored follow-up protocols or adjunctive therapies aimed at mitigating risk. Similarly, monitoring changes in fat compartments longitudinally could provide early warning signs of progression, prompting timely intervention.

On a molecular level, visceral fat’s metabolic activity could influence the tumor microenvironment through the secretion of adipokines, inflammatory cytokines, and growth factors that promote cancer cell survival and proliferation. Furthermore, insulin resistance linked to visceral obesity might exacerbate oncogenic pathways, creating a fertile ground for tumor progression. These mechanistic insights open avenues for translational research aimed at disrupting these pathways to improve patient outcomes.

Moreover, this study calls attention to the need for multidisciplinary approaches, combining oncologic care with metabolic and nutritional management. Strategically addressing visceral adiposity through lifestyle modifications, pharmacologic agents, or metabolic therapies could complement conventional cancer treatments, potentially altering disease course and enhancing survivorship.

The use of quantitative imaging biomarkers delineates a new frontier in oncologic assessment, exemplified by this research. Employing automated or semi-automated CT-based volumetrics enables objective, reproducible fat measurements, facilitating integration into clinical workflows. As imaging technologies evolve, the ability to extract meaningful metabolic and phenotypic data from standard diagnostic scans holds promise for revolutionizing personalized medicine.

Nevertheless, challenges remain. The study’s observational nature precludes definitive conclusions about causality, and further investigations are warranted to elucidate the biological mechanisms linking visceral fat to cancer progression and outcomes. Prospective trials exploring interventions aimed at modifying visceral adiposity in endometrial cancer patients could yield valuable clinical insights.

In addition, expanding the research to diverse populations and other tumor types might reveal broader applicability of visceral fat as a prognostic marker. Given the rising global burden of obesity and associated cancers, understanding fat’s role in oncogenesis and progression is paramount in developing effective strategies for prevention and management.

Taken together, the findings from this meticulous study spotlight visceral abdominal fat as a key player in endometrial cancer biology, bridging gaps between metabolic health and oncologic risk. They advocate for a paradigm shift in cancer diagnostics — one that embraces the complexity of body composition beyond conventional metrics and capitalizes on sophisticated imaging analyses to optimize patient care.

The revelations elucidated here are poised to spark heightened interest and further exploration within the scientific community, potentially guiding future clinical guidelines and research trajectories. As we deepen our grasp on the interplay between fat distribution and cancer behavior, the prospect of more accurate prognostication and targeted therapeutic strategies draws nearer, promising improved patient outcomes in the challenging landscape of endometrial cancer treatment.

Subject of Research:
Quantitative analysis of abdominal fat distribution via CT imaging in endometrial cancer patients, examining its relationship with tumor characteristics and prognosis from diagnosis to follow-up.

Article Title:
Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up.

Article References:
Fasmer, K.E., Sæterstøl, J., Ljunggren, M.B.S. et al. Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up. BMC Cancer 25, 879 (2025). https://doi.org/10.1186/s12885-025-14155-3

Image Credits:
Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-14155-3